Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter August 6, 2013

Any role for probiotics in the therapy or prevention of autoimmune diseases? Up-to-date review

  • Öner Özdemir EMAIL logo

Abstract

Probiotic use as capable preventive and therapeutic strategy in different diseases varying from allergic to autoimmune disease (AD) has been recently reported. Three interacting factors including an aberrant intestinal microbiota, a “leaky” intestinal mucosal barrier, and altered intestinal immune responsiveness have been suggested to be able to create a “perfect environment” for AD development. Regulation of intestinal microflora composition by probiotics offers the possibility to influence the development of mucosal/systemic immunity besides ADs. Moreover, with various strains of probiotics, development and/or stimulation of T helper type 2 (Th2)-mediated immune responses causing exacerbation of atopic disease have been described. Similarly, certain probiotics are known to stimulate Th1 immunity, which has been suggested as one of the mechanisms by which they can suppress Th2-mediated allergic diseases. Consequently, this presumed that excessive immunostimulation might aggravate or induce Th1-mediated immune responses and diseases such as type 1 diabetes, multiple sclerosis, and it might cause an additional safety issue. Although there is a large amount of conflicting data on the preventive/therapeutic effects of probiotics in ADs, there is fairly promising evidence to recommend as well. Thus, probiotic use cannot be generally recommended for primary prevention and therapy of ADs for now.

References

1. Özdemir Ö. Various effects of different probiotic strains in allergic disorders: an update from laboratory and clinical data. Clin Exp Immunol 2010;160:295–304.10.1111/j.1365-2249.2010.04109.xSearch in Google Scholar PubMed PubMed Central

2. Özdemir Ö. Any benefit of probiotics for autoimmune gastrointestinal diseases? J Pediatr Sci 2012;4:e160.Search in Google Scholar

3. Walsh KP, Brady MT, Finlay CM, et al. Infection with a helminth parasite attenuates autoimmunity through TGF-beta-mediated suppression of Th17 and Th1 responses. J Immunol 2009;183:1577–86.10.4049/jimmunol.0803803Search in Google Scholar PubMed

4. Billmann-Born S, Till A, Arlt A, et al. Genome-wide expression profiling identifies an impairment of negative feedback signals in the Crohn’s disease-associated NOD2 variant L1007fsinsC. J Immunol 2011;186:4027–38.10.4049/jimmunol.1000085Search in Google Scholar PubMed

5. Sgouroudis E, Kornete M, Piccirillo CA. IL-2 production by dendritic cells promotes Foxp3(+) regulatory T-cell expansion in autoimmune-resistant NOD congenic mice. Autoimmunity 2011;44:406–14.10.3109/08916934.2010.536795Search in Google Scholar PubMed

6. Schwartz RH. Natural regulatory T cells and self-tolerance. Nat Immunol 2005;6:327–30.10.1038/ni1184Search in Google Scholar PubMed

7. Okada H, Kuhn C, Feillet H, Bach JF. The “hygiene hypothesis” for autoimmune and allergic diseases: an update. Clin Exp Immunol 2010;160:1–9.10.1111/j.1365-2249.2010.04139.xSearch in Google Scholar PubMed PubMed Central

8. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002;347:911–20.10.1056/NEJMra020100Search in Google Scholar PubMed

9. Feillet H, Bach JF. Increased incidence of inflammatory bowel disease: the price of the decline of infectious burden? Curr Opin Gastroenterol 2004;20:560–4.10.1097/00001574-200411000-00010Search in Google Scholar PubMed

10. Bach JF. Protective role of infections and vaccinations on autoimmune diseases. J Autoimmun 2001;16:347–53.10.1006/jaut.2000.0478Search in Google Scholar PubMed

11. Singh B, Rabinovitch A. Influence of microbial agents on the development and prevention of autoimmune diabetes. Autoimmunity 1993;15:209–13.10.3109/08916939309019929Search in Google Scholar PubMed

12. Brugman S, Klatter FA, Visser JT, et al. Antibiotic treatment partially protects against type 1 diabetes in the Bio-Breeding-prone rat. Is the gut flora involved in the development of type 1diabetes? Diabetologia 2006;49:2105–08.Search in Google Scholar

13. Matsuzaki T, Takagi A, Ikemura H, Matsuguchi T, Yokokura T. Intestinal microflora: probiotics and autoimmunity. J Nutr 2007;137:3 Suppl 2:798S–802S.10.1093/jn/137.3.798SSearch in Google Scholar PubMed

14. Fasano A, Shea-Donohue T. Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. Nat Clin Pract Gastroenterol Hepatol 2005;2:416–22.10.1038/ncpgasthep0259Search in Google Scholar PubMed

15. Vaarala O, Atkinson MA, Neu J. The “Perfect Storm” for type 1 diabetes: the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. Diabetes 2008;57:2555–62.10.2337/db08-0331Search in Google Scholar PubMed PubMed Central

16. Joint FAO/WHO, author. Evaluation of health and nutritional properties of powder milk and live lactic acid bacteria. Food and Agriculture Organization of the United Nations and World Health Organization Expert Consultation Report. October 2001. http://www.fao.org/ag/agn/Probio/probio.htmSearch in Google Scholar

17. Lilly DM, Stillwell RH. Probiotics: growth-promoting factors produced by microorganisms. Science 1965;147:747–8.10.1126/science.147.3659.747Search in Google Scholar PubMed

18. Anukam KC, Osazuwa EO, Osadolor HB, Bruce AW, Reid G. Yogurt containing probiotic Lactobacillus rhamnosus GR-1 and L. reuteri RC-14 helps resolve moderate diarrhea and increases CD4 count in HIV/AIDS patients. J Clin Gastroenterol 2008;42:239–43.10.1097/MCG.0b013e31802c7465Search in Google Scholar PubMed

19. Al-Mendalawi MD, Heydarian F. Comparison between traditional yogurt and probiotic yogurt in non-inflammatory acute gastroenteritis. Saudi Med J 2010;31:1071–72.Search in Google Scholar

20. Lorea Baroja M, Kirjavainen PV, Hekmat S, Reid G. Anti-inflammatory effects of probiotic yogurt in inflammatory bowel disease patients. Clin Exp Immunol 2007;149:470–9.10.1111/j.1365-2249.2007.03434.xSearch in Google Scholar PubMed PubMed Central

21. Guarner F, Perdigon G, Corthier G, Salminen S, Koletzko B, Morelli L. Should yoghurt cultures be considered probiotic? Br J Nutr 2005;93:783–6.10.1079/BJN20051428Search in Google Scholar

22. Hitchins AD, McDonough FEM. Prophylactic and therapeutic aspects of fermented milk. Am J Clin Nutr 1989;49:675–84.10.1093/ajcn/49.4.675Search in Google Scholar PubMed

23. Pashapour N, Iou SG. Evaluation of yogurt effect on acute diarrhea in 6–24-month-old hospitalized infants. Turk J Pediatr 2006;48:115–18.Search in Google Scholar

24. Boudraa G, Benbouabdellah M, Hachelaf W, Boisset M, Desjeux JF, Touhami M. Effect of feeding yogurt versus milk in children with acute diarrhea and carbohydrate malabsorption. J Pediatr Gastroenterol Nutr 2001;33:307–13.10.1097/00005176-200109000-00015Search in Google Scholar PubMed

25. Sadrzadeh-Yeganeh H, Elmadfa I, Djazayery A, Jalali M, Heshmat R, Chamary M. The effects of probiotic and conventional yoghurt on lipid profile in women. Br J Nutr 2010;103:1778–83.10.1017/S0007114509993801Search in Google Scholar PubMed

26. Canche-Pool EB, Cortez-Gómez R, Flores-Mejía R, et al. Probiotics and autoimmunity: an evolutionary perspective. Med Hypotheses 2008;70:657–60.10.1016/j.mehy.2007.07.008Search in Google Scholar PubMed

27. Boerner BP, Sarvetnick NE. Type 1 diabetes: role of intestinal microbiome in humans and mice. Ann N Y Acad Sci 2011;1243:103–18.10.1111/j.1749-6632.2011.06340.xSearch in Google Scholar PubMed

28. Akerblom HK, Virtanen SM, Ilonen J, et al. Dietary manipulation of beta cell autoimmunity in infants at increased risk of type 1 diabetes: a pilot study. Diabetologia 2005;48:829–37.10.1007/s00125-005-1733-3Search in Google Scholar PubMed

29. Petrovsky N. Immunomodulation with microbial vaccines to prevent type 1 diabetes mellitus. Nat Rev Endocrinol 2010;6:131–8.10.1038/nrendo.2009.273Search in Google Scholar PubMed

30. Schiffer C, Lalanne AI, Cassard L, et al. A strain of Lactobacillus casei inhibits the effector phase of immune inflammation. J Immunol 2011;187:2646–55.10.4049/jimmunol.1002415Search in Google Scholar PubMed

31. Miele E, Pascarella F, Giannetti E, et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 2009;104:437–43.10.1038/ajg.2008.118Search in Google Scholar PubMed

32. Issazadeh-Navikas S, Teimer R, Bockermann R. Influence of dietary components on regulatory T cells. Mol Med 2012;18:95–110.10.2119/molmed.2011.00311Search in Google Scholar PubMed PubMed Central

33. Smits HH, Engering A, van der Kleij D, et al. Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. J Allergy Clin Immunol 2005;115:1260–7.10.1016/j.jaci.2005.03.036Search in Google Scholar PubMed

34. So JS, Kwon HK, Lee CG, et al. Lactobacillus casei suppresses experimental arthritis by down-regulating T helper 1 effector functions. Mol Immunol 2008;45:2690–9.10.1016/j.molimm.2007.12.010Search in Google Scholar PubMed

35. Kobayashi T, Suzuki T, Kaji R, et al. Probiotic upregulation of peripheral IL-17 responses does not exacerbate neurological symptoms in experimental autoimmune encephalomyelitis mouse models. Immunopharmacol Immunotoxicol 2012;34:423–33.10.3109/08923973.2010.617755Search in Google Scholar PubMed

36. Salminen SJ, Gueimonde M, Isolauri E. Probiotics that modify disease risk. J Nutr 2005;135:1294–8.10.1093/jn/135.5.1294Search in Google Scholar PubMed

37. Dotan I, Rachmilewitz D. Probiotics in inflammatory bowel disease: possible mechanisms of action. Curr Opin Gastroenterol 2005;21:426–30.Search in Google Scholar

38. Fedorak RN. Understanding why probiotic therapies can be effective in treating IBD. J Clin Gastroenterol 2008;42:Suppl 3 Pt 1:S111–15.10.1097/MCG.0b013e31816d922cSearch in Google Scholar PubMed

39. Isolauri E, Sütas Y, Kankaanpää P, Arvilommi H, Salminen S. Probiotics: effects on immunity. Am J Clin Nutr 2001;73:2 Suppl:444S–50S.10.1093/ajcn/73.2.444sSearch in Google Scholar PubMed

40. Rachmilewitz D, Katakura K, Karmeli F, et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004;126:520–8.10.1053/j.gastro.2003.11.019Search in Google Scholar PubMed

41. Aumeunier A, Grela F, Ramadan A, et al. Systemic Toll-like receptor stimulation suppresses experimental allergic asthma and autoimmune diabetes in NOD mice. PLoS One 2010;5:e11484.10.1371/journal.pone.0011484Search in Google Scholar PubMed PubMed Central

42. Schultz M, Linde HJ, Lehn N, et al. Immunomodulatory consequences of oral administration of Lactobacillus rhamnosus strain GG in healthy volunteers. J Dairy Res 2003;70:165–73.10.1017/S0022029903006034Search in Google Scholar

43. Baharav E, Mor F, Halpern M, Weinberger A. Lactobacillus GG bacteria ameliorate arthritis in Lewis rats. J Nutr 2004;134:1964–9.10.1093/jn/134.8.1964Search in Google Scholar PubMed

44. Rovensky J, Svik K, Stancikova M, Istok R, Ebringer L, Ferencik M. Treatment of experimental adjuvant arthritis with the combination of methotrexate and lyophilized Enterococcus faecium enriched with organic selenium. Folia Microbiol 2002;47:573–8.10.1007/BF02818800Search in Google Scholar PubMed

45. So JS, Kwon HK, Lee CG, et al. Lactobacillus casei suppresses experimental arthritis by down-regulating T helper 1 effector functions. Mol Immunol 2008;45:2690–9.10.1016/j.molimm.2007.12.010Search in Google Scholar PubMed

46. So JS, Lee CG, Kwon HK, et al. Lactobacillus casei potentiates induction of oral tolerance in experimental arthritis. Mol Immunol 2008;46:172–80.10.1016/j.molimm.2008.07.038Search in Google Scholar PubMed

47. Kato I, Endo-Tanaka K, Yokokura T. Suppressive effects of the oral administration of Lactobacillus casei on type II collagen-induced arthritis in DBA/1 mice. Life Sci 1998;63:635–44.10.1016/S0024-3205(98)00315-4Search in Google Scholar

48. Kano H, Kaneko T, Kaminogawa S. Oral intake of Lactobacillus delbrueckii subsp. bulgaricus OLL1073R-1 prevents collagen-induced arthritis in mice. J Food Prot 2002;65:153–60.10.4315/0362-028X-65.1.153Search in Google Scholar PubMed

49. Hatakka K, Martio J, Korpela M, et al. Effects of probiotic therapy on the activity and activation of mild rheumatoid arthritis–a pilot study. Scand J Rheumatol 2003;32:211–15.10.1080/03009740310003695Search in Google Scholar PubMed

50. Lee HJ, Waller RD, Stebbings S, et al. The effects of an orally administered probiotic on sulfasalazine metabolism in individuals with rheumatoid arthritis: a preliminary study. Int J Rheum Dis 2010;13:48–54.10.1111/j.1756-185X.2009.01449.xSearch in Google Scholar PubMed

51. Mandel DR, Eichas K, Holmes J. Bacillus coagulans: a viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial. BMC Comp Altern Med 2010;10:1–7.10.1186/1472-6882-10-1Search in Google Scholar PubMed PubMed Central

52. Nenonen MT, Helve TA, Rauma AL, Hanninen OO. Uncooked, lactobacilli-rich, vegan food and rheumatoid arthritis. Br J Rheumatol 1998;37:274–81.10.1093/rheumatology/37.3.274Search in Google Scholar PubMed

53. Garrett SL, Kennedy LG, Calin A. Patients’ perceptions of disease modulation by diet in inflammatory (rheumatoid arthritis/ankylosing spondylitis) and degenerative arthropathies. Br J Rheumatol 1993;32:Suppl 2:43.Search in Google Scholar

54. Scott FW, Cloutier HE, Kleemann R, et al. Potential mechanisms by which certain foods promote or inhibit the development of spontaneous diabetes in BB rats: dose, timing, early effect on islet area, and switch in infiltrate from Th1 to Th2 cells. Diabetes 1997;46:589–98.10.2337/diab.46.4.589Search in Google Scholar PubMed

55. Valladares R, Sankar D, Li N, et al. Lactobacillus johnsonii N6.2 Mitigates the development of Type 1 diabetes in BB-DP Rats. PLoS One 2010;5:10507.10.1371/journal.pone.0010507Search in Google Scholar PubMed PubMed Central

56. Calcinaro F, Dionisi S, Marinaro M, et al. Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. Diabetologia 2005;48:1565–75.10.1007/s00125-005-1831-2Search in Google Scholar PubMed

57. Matsuzaki T, Nagata Y, Kado S, et al. Prevention of onset in an insulin-dependent mellitus model, NOD mice, by oral feeding of Lactobacillus casei. Acta Pathol Microbiol Immunol Scand 1997;105:643–9.10.1111/j.1699-0463.1997.tb05066.xSearch in Google Scholar PubMed

58. Kawasaki E, Abiru N, Eguchi K. Prevention of type 1 diabetes: from the view point of beta cell damage. Diabetes Res Clin Pract 2004;66:Suppl 1:S27–32.10.1016/j.diabres.2003.09.015Search in Google Scholar

59. Ljungberg M, Korpela R, Ilonen J, Ludvigsson J, Vaarala O. Probiotics for the prevention of beta cell autoimmunity in children at genetic risk of type 1 diabetes–the PRODIA study. Ann N Y Acad Sci 2006;1079:360–4.10.1196/annals.1375.055Search in Google Scholar

60. Maassen CB, van Holten JC, Balk F, et al. Orally administered Lactobacillus strains differentially affect the direction and efficacy of the immune response. Vet Q 1998;20:Suppl 3:S81–3.10.1080/01652176.1998.9694976Search in Google Scholar

61. Lavasani S, Dzhambazov B, Nouri M, et al. A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells. PLoS One 2010;5:e9009.10.1371/journal.pone.0009009Search in Google Scholar

62. Kobayashi T, Kato I, Nanno M, et al. Oral administration of probiotic bacteria, Lactobacillus casei and Bifidobacterium breve does not exacerbate neurological symptoms in experimental autoimmune encephalomyelitis. Immunopharmacol Immunotoxicol 2010;32:116–24.10.3109/08923970903200716Search in Google Scholar

63. Ezendam J, de Klerk A, Gremmer ER, van Loveren H. Effects of Bifidobacterium animalis administered during lactation on allergic and autoimmune responses in rodents. Clin Exp Immunol 2008;154:424–31.10.1111/j.1365-2249.2008.03788.xSearch in Google Scholar

64. McGeachy MJ, Stephens LA, Anderton SM. Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory cells within the central nervous system. J Immunol 2005;175:3025–32.10.4049/jimmunol.175.5.3025Search in Google Scholar

65. Kidd PM. Multiple sclerosis, an autoimmune inflammatory disease: prospects for its integrative management. Altern Med Rev 2001;6:540–66.Search in Google Scholar

66. Schultz M, Veltkamp C, Dieleman LA, et al. Lactobacillus plantarum 299v in the treatment and prevention of spontaneous colitis in interleukin-10- deficient mice. Inflamm Bowel Dis 2002;8:71–80.10.1097/00054725-200203000-00001Search in Google Scholar

67. Madsen KL, Doyle JS, Jewell LD, Tavernini MM, Fedorak RN. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999;116:1107–11.10.1016/S0016-5085(99)70013-2Search in Google Scholar

68. Sheil B, MacSharry J, O’Callaghan L, et al. Role of interleukin (IL)-10 in probiotic-mediated immune modulation: an assessment in wild-type and IL-10 knock-out mice. Clin Exp Immunol 2006;144:273–80.10.1111/j.1365-2249.2006.03051.xSearch in Google Scholar PubMed PubMed Central

69. Sheil B, McCarthy J, O’Mahony L, et al. Is the mucosal route of administration esential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis. Gut 2004;53:694–700.10.1136/gut.2003.027789Search in Google Scholar PubMed PubMed Central

70. Welters CF, Heineman E, Thunnissen FB, van den Bogaard AE, Soeters PB, Baeten CG. Effect of dietary inulin supplementation on inflammation of pouch mucosa in patients with an ileal pouch-anal anastomosis. Dis Colon Rectum 2002;45:621–7.10.1007/s10350-004-6257-2Search in Google Scholar PubMed

71. Schultz M, Munro K, Tannock GW, et al. Effects of feeding a probiotic preparation (SIM) containing inulin on the severity of colitis and on the composition of the intestinal. microflora in HLA-B27 transgenic rats. Clin Diagn Lab Immunol 2004;11:581–7.Search in Google Scholar

72. Rachmilewitz D, Kermeli F, Takabayashi K, et al. Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology 2002;122:1428–41.10.1053/gast.2002.32994Search in Google Scholar PubMed

73. Huibregtse IL, Snoeck V, de Creus A, et al. Induction of ovalbumin-specific tolerance by oral administration of Lactococcus lactis secreting ovalbumin. Gastroenterology 2007;133:517–28.10.1053/j.gastro.2007.04.073Search in Google Scholar PubMed

74. Bibiloni R, Fedorak RN, Tannock GW, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005;100:1539–46.10.1111/j.1572-0241.2005.41794.xSearch in Google Scholar PubMed

75. Rolfe VE, Fortun PJ, Hawkey CJ, Bath-Hextall F. Probiotics for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2006:CD004826. Chichester, West Sussex: John Wiley and Sons Ltd.10.1002/14651858.CD004826.pub2Search in Google Scholar PubMed

76. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004;53:108–14.10.1136/gut.53.1.108Search in Google Scholar PubMed PubMed Central

77. Shen B, Brzezinski A, Fazio VW, et al. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. Aliment Pharmacol Ther 2005;22:721–8.10.1111/j.1365-2036.2005.02642.xSearch in Google Scholar PubMed

78. Gosselink MP, Schouten WR, van Lieshout LM, Hop WC, Laman JD, Ruseler-van Embden JG. Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis Colon Rectum 2004;47:876–84.10.1007/s10350-004-0525-zSearch in Google Scholar PubMed

79. Kuisma J, Mentula S, Jarvinen H, Kahri A, Saxelin M, Farkkila M. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther 2003;17:509–15.10.1046/j.1365-2036.2003.01465.xSearch in Google Scholar PubMed

80. Laake KO, Bjorneklett A, Aamodt G, et al. Outcome of four weeks’ intervention with probiotics on symptoms and endoscopic appearance after surgical reconstruction with a J-configurated ileal-pouch-anal-anastomosis in ulcerative colitis. Scan J Gastroenterol 2005;40:43–51.10.1080/00365520410009339Search in Google Scholar

81. Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999;354:635–9.10.1016/S0140-6736(98)06343-0Search in Google Scholar

82. Matthes H, Krummenerl T, Giensch M, Wolff C, Schulze J. Treatment of mild to moderate acute attacks of distal ulcerative colitis with rectally-administered E. coli Nissle 1917: Dose-dependent efficacy. Gastroenterology 2006;130:Suppl 2:A119.Search in Google Scholar

83. Kato K, Mizuno S, Umesaki Y, et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther 2004;20:1133–41.10.1111/j.1365-2036.2004.02268.xSearch in Google Scholar PubMed

84. Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 2003;22:56–63.10.1080/07315724.2003.10719276Search in Google Scholar PubMed

85. Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999;13:1103–08.10.1046/j.1365-2036.1999.00560.xSearch in Google Scholar PubMed

86. Zocco MA, dal Verme LZ, Cremonini F, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 2006;23:1567–74.10.1111/j.1365-2036.2006.02927.xSearch in Google Scholar PubMed

87. Malchow HA. Crohn’s disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn’s disease? J Clin Gastroenterol 1997;25:653–8.10.1097/00004836-199712000-00021Search in Google Scholar PubMed

88. Schultz M, Timmer A, Herfarth HH, et al. Lactobacillus GG in inducing and maintaining remission of Crohn’s disease. BMC Gastroenterol 2004;4:5.10.1186/1471-230X-4-5Search in Google Scholar PubMed PubMed Central

89. Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn’s disease. Dig Dis Sci 2000;45:1462–4.10.1023/A:1005588911207Search in Google Scholar

90. Bousvaros A, Guandalini S, Baldassano RN, et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn’s disease. Inflamm Bowel Dis 2005;11:833–9.10.1097/01.MIB.0000175905.00212.2cSearch in Google Scholar PubMed

91. Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn’s disease: a randomised controlled trial with Lactobacillus GG. Gut 2002;51:405–09.10.1136/gut.51.3.405Search in Google Scholar

92. Van Gossum A, Dewit O, Louis E, et al. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn’s disease after ileo-caecal resection. Inflamm Bowel Dis 2007;13:135–42.10.1002/ibd.20063Search in Google Scholar

93. Marteau P, Lemann M, Seksik P, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn’s disease: a randomised, double blind, placebo controlled GETAID trial. Gut 2006;55:842–7.10.1136/gut.2005.076604Search in Google Scholar

94. Campieri M, Rizzello F, Venturi A, et al. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn’s disease: a randomized controlled study vs mesalamine. Gastroenterology 2000;118:G4179.10.1016/S0016-5085(00)85267-1Search in Google Scholar

95. Di Cagno R, Rizzello CG, De Angelis M, et al. Use of selected sourdough strains of Lactobacillus for removing gluten and enhancing the nutritional properties of gluten-free bread. J Food Prot 2008;71:1491–5.10.4315/0362-028X-71.7.1491Search in Google Scholar

96. De Angelis M, Rizzello CG, Fasano A, et al. VSL#3 probiotic preparation has the capacity to hydrolyze gliadin polypeptides responsible for Celiac Sprue. Biochim Biophys Acta 2006;1762:80–93.10.1016/j.bbadis.2005.09.008Search in Google Scholar PubMed

97. Lindfors K, Blomqvist T, Juuti-Uusitalo K, et al. Live probiotic Bifidobacterium lactis bacteria inhibit the toxic effects induced by wheat gliadin in epithelial cell culture. Clin Exp Immunol 2008;152:552–8.10.1111/j.1365-2249.2008.03635.xSearch in Google Scholar PubMed PubMed Central

98. Ishibashi N, Yamazaki S. Probiotics and safety. Am J Clin Nutr 2001;73:Suppl:465S–70S.10.1093/ajcn/73.2.465sSearch in Google Scholar PubMed

99. Kunz AN, Noel JM, Fairchok MP. Two cases of Lactobacillus bacteremia during probiotic treatment of short gut syndrome. J Pediatr Gastroenterol Nutr 2004;38:457–8.10.1097/00005176-200404000-00017Search in Google Scholar PubMed

100. Land MH, Rouster-Stevens K, Woods CR, Cannon ML, Cnota J, Shetty AK. Lactobacillus sepsis associated with probiotic therapy. Pediatrics 2005;115:178–81.10.1542/peds.2004-2137Search in Google Scholar PubMed

101. Thompson C, McCarter YS, Krause PJ, Herson VC. Lactobacillus acidophilus sepsis in a neonate. J Perinatol 2001;21:258–60.10.1038/sj.jp.7200509Search in Google Scholar

102. Broughton RA, Gruber WC, Haffar AA, Baker CJ. Neonatal meningitis due to Lactobacillus. Pediatr Infect Dis 1983;2:382–4.10.1097/00006454-198309000-00012Search in Google Scholar

103. Maassen CB, Claassen E. Strain-dependent effects of probiotic lactobacilli on EAE autoimmunity. Vaccine 2008;26:2056–7.10.1016/j.vaccine.2008.02.035Search in Google Scholar

104. Food and Agriculture Organization, World Health Organization. The Food and Agriculture Organization of the United Nations and the World Health Organization Joint FAO/WHO Working Group report on drafting guidelines for the evaluation of probiotics in food. FAO/WHO Report No. 4-30-2002.Search in Google Scholar

105. Salminen S, von Wright A, Morelli L, et al. Demonstration of safety of probiotics: a review. Int J Food Microbiol 1998;44:93–106.10.1016/S0168-1605(98)00128-7Search in Google Scholar

106. Taylor A, Dunstan J, Prescott S. Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization in high-risk children: a randomized controlled trial. J Allergy Clin Immunol 2007;119:184–91.10.1016/j.jaci.2006.08.036Search in Google Scholar PubMed

107. Kopp MV, Hennemuth I, Heinzmann A, Urbanek R. Randomized, double-blind, placebo-controlled trial of probiotics for primary prevention: no clinical effects of Lactobacillus GG supplementation. Pediatrics 2008;121:e850–6.10.1542/peds.2007-1492Search in Google Scholar PubMed

108. Kukkonen AK, Kuitunen M, Savilahti E, Pelkonen A, Malmberg P, Mäkelä M. Airway inflammation in probiotic-treated children at 5 years. Pediatr Allergy Immunol 2011;22:249–51.10.1111/j.1399-3038.2010.01079.xSearch in Google Scholar PubMed

109. Baken KA, Ezendam J, Gremmer ER, et al. Evaluation of immunomodulation by Lactobacillus casei Shirota: immune function, autoimmunity and gene expression. Int J Food Microbiol 2006;112:8–18.10.1016/j.ijfoodmicro.2006.06.009Search in Google Scholar PubMed

110. Okitsu-Negishi S, Nakano I, Suzukim K, Hashira S, Abe T, Yoshino K. The induction of cardioangitis by Lactobacillus casei cell wall in mice: I. The cytokine production from murine macrophages by Lactobacillus casei cell wall extract. Clin Immunol Immunopathol 1996;78:30–40.10.1006/clin.1996.0005Search in Google Scholar PubMed

111. Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements. 21 C.F.R.111, 2007.Search in Google Scholar

112. Sanders ME, Akkermans LM, Haller D, et al. Safety assessment of probiotics for human use. Gut Microbes 2010;1.3:164–85.10.4161/gmic.1.3.12127Search in Google Scholar PubMed PubMed Central

113. Zhou JS, Gill HS. Immunostimulatory probiotic Lactobacillus rhamnosus HN001 and Bifidobacterium lactis HN019 do not induce pathological inflammation in mouse model of experimental autoimmune thyroiditis. Int J Food Microbiol 2005;103:97–104.10.1016/j.ijfoodmicro.2004.11.031Search in Google Scholar PubMed

Received: 2012-10-14
Accepted: 2013-07-02
Published Online: 2013-08-06

©2013 by Walter de Gruyter Berlin / Boston

Downloaded on 19.4.2024 from https://www.degruyter.com/document/doi/10.1515/jcim-2012-0054/html
Scroll to top button